Publicaciones

Javier Cotignola

  1. Antico VG, Gueron G, Cotignola J, Vázquez E. Altered Signaling Pathways in Prostate Cancer Drive Metabolic Fate. International Journal of Scientific Research. September, 2017. In press.
  2. Paez AV, Pallavicini C, Schuster F, Valacco MP, Giudice J, Ortiz EG, Anselmino N, Labanca E, Binaghi M, Salierno M, Martí MA, Cotignola JH, Woloszynska-Read A, Bruno L, Levi V, Navone N, Vazquez ES, Gueron G.Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer. Cell Death Dis. 2016 Dec 29;7(12):e2570. doi: 10.1038/cddis.2016.420.
  3. Luce LN, Abbate M, Cotignola J*, Giliberto F*. Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations. Oncotarget. 2017 Jan 3;8(1):145-155. doi: 10.18632/oncotarget.10426. [Epub ahead of print Jul 2016].
  4. Leonardi DB*, Abbate M*, Riccheri MC, Nuñez M, Alfonso G, Gueron G, De Siervi A, Vazquez E, Cotignola J. Improving risk stratification of patients with childhood Acute Lymphoblastic Leukemia: Glutathione-S-Transferases polymorphisms are associated with increased risk of relapse. Oncotarget. 2017 Jan 3;8(1):110-117. doi: 10.18632/oncotarget.8606. [Epub ahead of print Apr 2016].
  5. Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. Curr Pharm Biotechnol. 2015;16(6):553-63.
  6. Cotignola J, Leonardi DB, Nuñez M, De Siervi A, Alfonso G, Riccheri MC, Vazquez E. Los Polimorfismos en los genes GSTP1, GSTM1 y GSTT1 están asociados con el riesgo de sufrir recaídas en los pacientes pediátricos con Leucemia Linfoblástica Aguda. Hematología. 2014; 18(2): 111-116.
  7. Moiola CP, De Luca P, Zalazar F, Cotignola J, Rodriguez-Segui S, Gardner K, Meiss R, Vallecorsa P, Pignataro O, Mazza O, Vazquez ES, De Siervi A. Prostate tumor growth is impaired by CtBP1 depletion in high fat diet fed mice. Clin Cancer Res. 2014 Aug 1;20(15):4086-95. doi: 10.1158/1078-0432.CCR-14-0322. Epub 2014 May 19.
  8. Gueron G, Giudice J, Elguero B, Valacco P, Paez A, Toscani AM, Jaworski F, Coluccio Leskow F, Cotignola J, Marti M, Binaghi M, Navone N, Vazquez E. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget. 2014 Jun 30;5(12):4087-4102.
  9. Luce LN, Ottaviani D, Ferrer M, Szijan I, Cotignola J and Giliberto F. Molecular diagnosis of dystrophinopathies using a multi-technique analysis algorithm. Muscle Nerve. 2014 Feb;49(2):249-256. Epub 2013 May 20. doi: 10.1002/mus.23906.
  10. Cotignola J, Leonardi DB*, Shahabi A*, Acuña A, Stern MC, Navone N, Scorticati C, De Siervi A, Mazza O and Vazquez E. Glutathione-S-Transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):28-34. doi: 10.1038/pcan.2012.45. Epub 2012 Nov 13.
  11. Moiola C, De Luca P, Cotignola J, Gardner K, Vazquez E and De Siervi A. Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cell Physiol Biochem. 2012;30(3):596-608. doi: 10.1159/000341441. Epub 2012 Jul 27.
  12. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC and Orlow I. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol. 2012 May;132(5):1471-1478. doi: 10.1038/jid.2012.15. Epub 2012 Feb 16.
  13. De Luca P, Vazquez E, Moiola C, Zalazar F, Cotignola J, Gueron G, Gardner K and De Siervi A. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol Cancer Res. 2011 Aug;9(8):1078-1090. doi: 10.1158/1541-7786.MCR-11-0155. Epub 2011 Jun 23.
  14. Mandelcorn-Monson R, Marrett L, Kricker A, Armstrong BK, Orlow I, Goumas C, Paine S, Rosso S, Thomas N, Millikan RC, Pole JD, Cotignola J, Rosen C, Kanetsky PA, Lee-Taylor J, Begg CB and Berwick M. Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiol. 2011 Dec;35(6):e105-110. doi: 10.1016/j.canep.2011.03.003. Epub 2011 May 25.
  15. Orlow I, Tommasi D, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam K, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE and Begg CB. Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. J Invest Dermatol. 2009 Aug;129(8):1972-1982. doi: 10.1038/jid.2009.4. Epub 2009 Mar 12.
  16. Machiavelli G, Cotignola J, Danilowicz K, Carbonara C, Paes de Lima A, Basso A, Bruno OD and Szijan I.Expression of p16(INK4A) gene in human pituitary tumours. Pituitary. 2008;11(1):71-75. Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M and Orlow I. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Med Genet. 2007 Mar 8;8:10.
  17. Cotignola J, Roy P, Patel A, Ishill N, Shah S, Houghton A, Coit D, Halpern A, Busam K, Berwick M and Orlow I. Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression. J Negat Results Biomed. 2007 Oct 24;6:9.
  18. Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Wilcox H, Busam K, From L, Berwick M and GEM Study Group. CDKN2A Germline Mutations in Individuals with Cutaneous Malignant Melanoma. J Invest Dermatol. 2007 May;127(5):1234-1243. Epub 2007 Jan 11.

Comentarios cerrados